We are live on ! Find out more
ADIL

Adial Pharmaceuticals

14 hedge funds and large institutions have $236K invested in Adial Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

0% more funds holding

Funds holding: 1414 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0.44% less ownership

Funds ownership: 0.87%0.43% (-0.44%)

52% less capital invested

Capital invested by funds: $495K → $236K (-$259K)

Holders
14
Holders Change
Holders Change %
0%
% of All Funds
0.2%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
4
Reduced
1
Closed
4
Calls
Puts
Net Calls
Net Calls Change

ADIL Hedge Fund Activity: Q1 2024 in Review

14 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q1 2024, worth a combined $236K — down 52% from $495K a quarter earlier.

Fund positioning in ADIL was balanced in Q1 2024: 4 funds opened new positions, 4 closed out, 4 added to existing stakes and 1 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $53.6K. The largest seller was Armistice Capital, exiting entirely with an estimated $296K sold.

  • 14 institutional investors held Adial Pharmaceuticals (ADIL) as of Q1 2024, unchanged from Q4 2023.
  • Funds reported $236K of Adial Pharmaceuticals stock for Q1 2024, down 52% quarter-over-quarter.
  • 4 funds opened new Adial Pharmaceuticals positions in Q1 2024 and 4 closed out, a net change of 0 holders.
  • The largest Adial Pharmaceuticals buyer in Q1 2024 was HRT Financial, an estimated $53.6K added.
  • The largest Adial Pharmaceuticals seller in Q1 2024 was Armistice Capital, an estimated $296K sold.

Based on aggregated 13F filings for Q1 2024.